Skip to main content

Incyte Corp

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

Did you know?

Holds 89.3x more cash than debt — a strong balance sheet.

Current Price

$96.91

+1.72%

GoodMoat Value

$271.40

180.1% undervalued
Profile
Valuation (TTM)
Market Cap$19.29B
P/E13.47
EV$14.21B
P/B3.73
Shares Out199.01M
P/Sales3.60
Revenue$5.36B
EV/EBITDA8.18

Incyte Corp (INCY) Financial Statements

GoodMoat Analysis

Based on data as of March 26, 2026

Incyte Corp demonstrates strong fundamental quality with exceptional profitability and a pristine balance sheet. Revenue growth is robust, but the key question for a value investor is the durability of this growth beyond its core drug.

Read full analysis
Incyte's financial quality is high, scoring favourably on several key indicators from the framework. The company is highly profitable, with a 25.0% profit margin and a 29.5% operating margin, which are strong for any industry. Its Return on Equity of 24.9% far exceeds the 15-20% high-quality threshold, indicating excellent use of shareholder capital. Free cash flow generation is robust, with a 7.5% FCF yield suggesting healthy cash conversion. The balance sheet is exceptionally strong, with a negligible Debt/Equity ratio of 0.007, signalling virtually no financial risk and ample capacity for investment or strategic moves. Regarding growth, the 27.8% YoY revenue growth is impressive and well above the 20% threshold for sustained high growth. However, the framework emphasizes assessing if growth is driven by durable moat advantages. For Incyte, this requires investigating whether growth is solely dependent on its flagship product, Jakafi, or if it is successfully diversifying its pipeline—a critical factor for long-term growth sustainability that the provided data alone cannot confirm. Overall, the financial health is very strong, but the growth assessment hinges on pipeline visibility.

INCY Financial Data

EBITDA$1.87B
Revenue (TTM)$5.36B
Gross Profit (TTM)$4.96B
Gross Margin
Operating Margin29.46%
ROE27.71%
ROA20.58%
Debt/Equity0.01
Current Ratio3.32
FCF$1.35B
FCF Yield7.02%
Piotroski F-Score
Rev/Share (TTM)$26.94
50-Day MA$95.73
200-Day MA$93.49
Shares Outstanding0.20B

INCY Computed Insights

FCF$1.35B
FCF Growth Rate13.53%
EPS Growth (CAGR)19.27%
WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

INCY Financial Statements & Data

Incyte Corp (INCY) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Incyte Corp's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $5.36B. Gross profit (TTM) is $4.96B. EBITDA is $1.87B. Earnings per share (EPS) is $6.41. The P/E ratio is 13.47. Market capitalization is $19.29B.

Free cash flow (FCF) is $1.35B. FCF growth rate is 13.53%. EPS growth CAGR is 19.27%. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Incyte Corp's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.